[1]
Stewart BW, and Wild CP. World cancer report IARC Publisher and Distributed by WHO Press, 2014.
[2]
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. Cancer J Clin 2015; 65(2): 87-108.
[3]
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 2013; 13(10): 714-26.
[4]
Sui X, Chen R, Wang Z, et al. Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis 2013; 4: e838.
[5]
Liu B, Ezeogu L, Zellmer L, Yu B, Xu N, Joshua LD. Protecting the normal in order to better kill the cancer. Cancer Med 2015; 4(9): 1394-4403.
[6]
Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002; 8: 2725-34.
[7]
Plummer ER, Middleton MR, Jones C. TMZ pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyl transferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005; 11(9): 3402-19.
[8]
Yoshimoto K, Mizoguchi M, Hata N, et al. Complex DNA repair pathways as possible therapeutic targets to overcome TMZ resistance in glioblastoma. Front Oncol 2012; 2: 186.
[9]
Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, and Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005; 65(14): 6394-400.
[10]
Barciszewska A-M, Gurda D, Głodowicz P, Nowak S, Naskręt-Barciszewska MZ. A New Epigenetic Mechanism of Temozolomide Action in Cells. PLoS One 2015; 10(8): e0136669.
[11]
Liu X1. Shi Y, Guan R. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008; 6(10): 1621-9.
[12]
Jo MY, Kim YG, Kim Y, et al. Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms. Mol Med Rep 2012; 6(1): 88-92.
[13]
Helleday T, Petermann E, Lundin C, Hodgson B, and Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8(3): 193-204.
[14]
Aayushi J, Jahagirdar D, Nilendu P, Sharma NK. Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics. Expert Rev Anticancer Ther 2017; 17(9): 815-25.
[15]
O’Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell 2015; 60(4): 547-60.
[16]
Jain A, Yadav S, Beig M, Purohit S, Sharma NK. Base excision repair manipulation in breast carcinoma: A prospective avenue to potentiate genome insulting approach. Oncomedicine 2017; 2: 42-51.
[17]
Gavande NS, VanderVere-Carozza PS, Hinshaw HD, et al. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 2016; 160: 65-83.
[18]
Lindahl T. The intrinsic fragility of DNA (Nobel Lecture). Angew Chem Int Ed Engl 2016; 55(30): 8528-34.
[19]
Çağlayan M, Wilson SH. Oxidant and environmental toxicant-induced effects compromise DNA ligation during base excision DNA repair. DNA Repair (Amst) 2015; 35: 85-9.
[20]
Madhusudan S, Smart F, Shrimpton P, et al. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 2005; 33(15): 4711-24.
[21]
Chen X, Zhong S, Zhu X, et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res 2008; 68(9): 3169-77.
[22]
Svilar D, Dyavaiah M, Brown AR, et al. Alkylation sensitivity screens reveal a conserved cross-species functionome. Mol Cancer Res 2012; 10(12): 1580-96.
[23]
Strober W. Trypan blue exclusion test of cell viability Curr Protoc Immunol 2001 May; Appendix 3: Appendix 3B. doi: 10.1002/0471142735.ima03bs 21.
[24]
Louis KS, Siegel AC. Cell viability analysis using trypan blue: manual and automated methods. Methods Mol Biol 2011; 740: 7-12.
[25]
Lyons AB, Blake SJ, Doherty KV. Flow cytometric analysis of cell division by dilution of CFSE and related dyes Curr Protoc Cytom 2013; Chapter 9: Unit 11. doi: 10.1002/04711 42956.cy0911s64.
[26]
Sharma NK, Thomas T, Lebedeva M, et al. Intrinsic DNA ligase III and mitochondrial DNA repair defects in Ataxia Telangiectasia. DNA Repair (Amst) 2014; 13: 22-31.
[27]
Roukos V, Pegoraro G, Voss TC, Misteli T. Cell cycle staging of individual cells by fluorescence microscopy. Nat Protoc 2015; 10(2): 334-48.
[28]
Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: Mechanism of action and related DNA repair systems. Pharmacol Res 2007; 56(4): 275-87.
[29]
Adibi H, Majnooni MB, Mostafaie A, Mansouri K, Mohammadi M. Synthesis, and in-vitro cytotoxicity studies of a series of triazene derivatives on human cancer cell lines. Iran J Pharm Res 2013; 12(4): 695-703.
[30]
Purohit S, Devashree J, Azad K, Sharma NK. In vitro single-strand DNA damage and cancer cell cytotoxicity effects of Temozolomide. Oncomedicine 2017; 2: 102-10.
[31]
DiPaola RS. To arrest or not to G(2)-M Cell-cycle arrest: Commentary re: Tyagi AK. et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res 2002; 8: 3512-9. Clin Cancer Res 2002; 8(11): 3311-4.
[32]
Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLH, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33: 9045-51.
[33]
Fink D, Aebi S, and Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
[34]
Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999; 5: 2908-17.
[35]
Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ, Gerson SL. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res 2001; 485(4): 269-81.
[36]
Pandey M, Kumar S, Goldsmith G. Identification and characterization of novel ligase I inhibitors. Mol Carcinog 2017; 56(2): 550-66.
[37]
Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 2003; 23(22): 8306-15.
[38]
Çıtışlı V, Dodurga Y, Eroğlu C, Seçme M, Avcı ÇB, Şatıroğlu-Tufan NL. TMZmay induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells. Tumour Biol 2015; 36(9): 6765-72.
[39]
Srivastava M1, Nambiar M, Sharma S, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012; 151: 1474-87.
[40]
Chen TC, Cho HY, Wang W, et al. A novel temozolomide–perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol Cancer Ther 2014; 13(5): 1181-93.
57
2